New therapies for Chronic Kidney Disease could be developed sooner by using a different definition for kidney disease during clinical trials, a new study suggests.
Data of 1.7 million participants was analysed to compare whether a decline in estimated kidney function or a doubling of serum creatinine was a more reliable indicator of kidney disease progression.
Researchers found the current serum-creatinine standard used in clinical trials only occurred in less than 1% of participants in the two-year baseline period.
This compared to the 7% in participants evaluated with decline in kidney function.
If adopted, the new definition could shorten some clinical trials and encourage more clinical trials for kidney disease.
Read more at Johns Hopkins University Bloomberg School of Public Health